Who can enter
- Male and female participants with recurrent or refractory classical Hodgkin lymphoma or non-Hodgkin lymphoma
- Age: under 18 years of age (Part A) and no older than 30 years of age (Part B)
Goal
The purpose of this study is to learn more about the safety and effectiveness (ie, how well the drug works) of relatlimab and nivolumab in patients with classical Hodgkin lymphoma (cHL) or non-Hodgkin lymphoma (NHL) that has either come back (relapsed) or did not respond to initial treatment (refractory) (R/R).
Background
There is currently no general treatment approach for pediatric and adolescent patients with relapsed or refractory cHL. There is little consistency, with no clear recommendation on the best treatment, and few available options. So new treatment options are needed.
Study details
Official title
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Cancer type
Recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma
Phase
1/2
Maximum number of patients
This study requires 10 subjects for part A and up to 66 subjects for part B, of whom 2 are expected to participate in the Netherlands.
Start date
October 10, 2023
Status
Open
Local principal investigator
Dr. A. Beishuizen
Sponsor
Bristol-Myers Squibb
Approval
The study of this new treatment has been reviewed by an accredited medical research ethics committee. This committee has decided that it is justified to ask patients to participate in this study. More information can be found at: CCMO and Government of the Netherlands.
Trial registry number
ClinicalTrials.gov Identifier: NCT05255601
In order to participate in a study please contact your/your child’s doctor.
Last reviewed
October 10, 2023
